Anxiety treatment in the US is changing dramatically after almost 20 years of a stagnant field of medication options. Both researchers and clinicians say that new anxiety treatment methods, such as psychedelic, assisted therapies and digital therapeutics, are revitalizing the hope of people who have not responded to standard care. A recent survey reports that an LSD, derived compound, MM120, has demonstrated very successful results in a Phase 2 trial for generalized anxiety disorder, providing fast and sustained symptom relief for weeks following a single dose.
The new wave of anxiety treatment also embraces psilocybin, assisted therapy, which involves a guided psychedelic session combined with a structured psychotherapy program for anxiety and related distress alleviation. Meanwhile, prescription digital therapeutics such as DaylightRx offer CBT, based anxiety treatment via an app and in clinical trials show anxiety recovery rates of more than 70% along with better sleep, mood, and general well, being. These instruments can help people who are on long waitlists or reside in remote areas to get anxiety treatments that are supported by evidence.
Specialists warn that most of these anxiety treatments are only at the research stage or are seeking regulatory approvals and that they should not be considered as a substitute for already established therapies such as CBT, medication, and lifestyle changes. However, the momentum is obvious: after years of limited innovation, the anxiety treatment landscape is
Source: New research on anxiety treatment innovations and psychedelic‑based approaches, Digital therapeutics and MM120 trial data for anxiety treatment
Leave a Comment